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Abstract 
Genina N., 2010. Ultrasound-assisted surface engineering of pharmaceutical powders. 
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ISBN 978-952-10-6413-5 (paperback), ISBN 978-952-10-6414-2 (PDF), ISSN 1795-7079 
 
 
Effective processing of powdered particles can facilitate powder handling and result in 
better drug product performance, which is of great importance in the pharmaceutical 
industry where the majority of active pharmaceutical ingredients (APIs) are delivered as 
solid dosage forms. The purpose of this work was to develop a new ultrasound-assisted 
method for particle surface modification and thin-coating of pharmaceutical powders. The 
ultrasound was used to produce an aqueous mist with or without a coating agent. 
By using the proposed technique, it was possible to decrease the interparticular 
interactions and improve rheological properties of poorly-flowing water-soluble powders 
by aqueous smoothing of the rough surfaces of irregular particles. In turn, hydrophilic 
polymer thin-coating of a hydrophobic substance diminished the triboelectrostatic charge 
transfer and improved the flowability of highly cohesive powder. To determine the coating 
efficiency of the technique, the bioactive molecule β-galactosidase was layered onto the 
surface of powdered lactose particles. Enzyme-treated materials were analysed by 
assaying the quantity of the reaction product generated during enzymatic cleavage of the 
milk sugar. A near-linear increase in the thickness of the drug layer was obtained during 
progressive treatment. Using the enzyme coating procedure, it was confirmed that the 
ultrasound-assisted technique is suitable for processing labile protein materials. In 
addition, this pre-treatment of milk sugar could be used to improve utilization of lactose-
containing formulations for populations suffering from severe lactose intolerance. 
Furthermore, the applicability of the thin-coating technique for improving homogeneity of 
low-dose solid dosage forms was shown. The carrier particles coated with API gave rise to 
uniform distribution of the drug within the powder. The mixture remained homogeneous 
during further tabletting, whereas the reference physical powder mixture was subject to 
segregation.  
In conclusion, ultrasound-assisted surface engineering of pharmaceutical powders can 
be effective technology for improving formulation and performance of solid dosage forms 
such as dry powder inhalers (DPI) and direct compression products. 
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1 Introduction  
Powder technology is an important research area of pharmaceutical manufacturing, since 
solid dosage forms are the most common preparations for drug administration. Nowadays 
in the pharmaceutical industry, quality by design and economic pressures demand 
optimized production from the outset of a project to prevent delays in new drug approvals 
by regulatory agencies (Freeman, 2010). Powder characterization can give rise to better 
understanding of critical parameters during the earliest stages of product development. 
Effective processing of powdered substances can lead to enhancement in powder 
performance and thus help to prepare a clinically effective formulation, develop robust 
technologies and manufacture a high quality product.  
It is evident that powder properties, such as particle size, shape, surface and density as 
well as flowability and compressibility can be critical for successful production of solid 
dosage forms. By improving powder morphological and rheological characteristics at the 
beginning of the drug development process, it is possible to avoid powder handling 
problems and to obtain a product with desirable properties in a cost-effective way. 
Effective treatment of particle surfaces may be one option for affecting powder behaviour 
during industrial processes. Preparation of particles with a modified exterior can prevent a 
tendency for them to interact. It may result in better flow and aerosolization properties that 
are crucial in the manufacture of newer delivery technologies such as dry powder inhalers 
(DPIs) (Podczeck, 1998; Schiavone et al., 2004; Edge et al., 2008). In addition, optimized 
flowability of powders is important in the preparation of tablets and capsules of uniform 
mass and content (Prescott and Hossfeld, 1994). Functional coating and homogeneous 
distribution of the active pharmaceutical ingredient (API) in the production of low-dose 
solid dosage forms can be another set of issues that makes surface engineering of 
powdered carrier particles valuable (Grawe et al., 2001; Chan and Chew, 2003). In 
addition, efficient processing of particle surfaces could avoid the time, energy and cost 
consuming granulation step and allow the direct compression of a physical powder blend.  
The main goal of this work was to increase insight into the effects of particle surface 
engineering on the performance and quality of powders during pharmaceutical processing. 
Various visual and analytical methods were used to study changes in the technical 
properties of powdered materials and the relationship between these changes and those in 
the particle surface morphology. Carrier particle surface coating with APIs was used to 
increase the utilization of lactose in some pharmaceutical formulations and to improve 
content uniformity of low-dose solid dosage forms. The above-mentioned modifications of 
particle surface properties were done using an ultrasound-assisted technique developed 
during this work. The literature review is focused on the theoretical characterization of 
powder properties and methods used to improve powder behaviour during drug 
development. 
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2 Literature review 
2.1 Pharmaceutical powders and granules 
To date the majority of medicines are available as solid dosage forms such as powders and 
their derived products (e.g. granules, pellets, tablets and capsules). However, powdered 
materials possess some unfavourable properties that must be overcome during drug 
development and design to maintain satisfactory performance of powders in dosage forms. 
Therefore, an understanding of particle properties is fundamentally important to enable 
their effective modification and further improvement of powder bulk behaviour. 
A powder is a multiple system consisting of solid and gaseous phases. Powders have 
characteristics related to both phases. Powdered materials can deform permanently, acting 
as solids, and can be compressed, behaving as gases. In addition, they can flow and 
possess rheological properties typical for liquids. Pharmaceutical powders are electrical 
insulators. They are good at generating, holding and transferring particle surface charge. 
Powders are considered to be composed of a large number of fine particles with a 
maximum dimension of less than 1000 µm (Staniforth, 2002). Powders consisting of 
particles of less than 100 µm are considered to be very interactive with each other and 
with the walls of handling devices, which causes problems during processing of these 
materials, especially in conditions of very low humidity. On the other hand, powders of 
particle size greater than 250 µm are less electrostatic and rather free flowing (Antikainen, 
2003). Granular material is the product of size enlargement processes with particle 
dimensions greater than 1000 µm (Staniforth, 2002). 
2.1.1 Particle size and shape 
The particle morphology of powders plays a critical role in the performance of APIs and 
excipients during the manufacturing of dosage forms. Obtaining detailed information 
about particle size and shape of raw material is important if the final product contains 
solid particulates (Heng and Chan, 1997). Different methods such as microscopy in 
connection with image analysis, sieving, light scattering, sedimentation, electrical sensing 
and photon correlation spectroscopy have been used to measure the size of particles (Heng 
and Chan, 1997). Among them, the first three have been the most widely-used techniques. 
However, all methods have their advantages and special limitations. 
Characterization of spherically-shaped particles with a narrow size distribution is easy 
to perform by microscopic methods along with image analysis. However, the shape of 
particles is usually not regular, and being elongated, acicular, angular or a mix, thereof 
makes determination of particle size difficult. Therefore, equivalent spherical diameters of 
different particle properties, such as volume, surface area and projected area, have been 
used to describe the particle size of powdered materials (Laitinen, 2003). The common 
treatment of image data provides quantitative descriptions of particle shape such as aspect 
or elongation ratio (length/breadth), bulkiness factor (area/(length + breadth)) and shape or 
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form factor (4pi area/(perimeter)²) (Heng and Chan, 1997). Aspect ratio shows the 
deviation from a spherical shape towards an elongated form. The bulkiness factor provides 
an indication of solidity. The shape factor gives a measure of sphericity. The ideal sphere 
has form factor and aspect ratio values of unity. In spite of these valuable data, particle 
image analysis is a relatively slow and tedious process, and flaws and statistical errors in 
particle size determination can happen due to a preferred orientation of the particles, 
insufficient dispersion of powder samples and an inadequate number of powdered units. A 
novel approach based on analysis of digital images of powder surfaces was introduced for 
particle size analysis of pharmaceutical materials (Laitinen et al., 2002). The method is 
fast, non-destructive and requires less than a half gram of the sample. However, the 
resolution of this technique is limited and the accuracy of the applied models depends on 
the quality of the results obtained from the reference methods. Preparation of powder 
surface samples may be a source of error as well (Laitinen et al., 2004).  
Sieving is an appropriate method if the amount of material is not limited. However, it 
is a time-consuming method, in which inaccuracies may occur due to incorrect sieve load 
and sieving time, aggregation of highly cohesive powder and a tendency of particles to 
pass through the mesh on their smaller cross-sectional area (Heng and Chan, 1997).  
Nowadays the popularity of the light scattering method is related to its quick 
performance, which gives reproducible results for particle size distribution. The 
difficulties of this technique can be associated with finding a suitable solvent for 
dispersion of the powder in the case of particle size determination in liquids. 
Agglomeration of particles and a large sample size can be problematic for measurement of 
particle dimensions using particles in an air-based method.  
2.1.2 Particle surface  
A surface is a boundary that separates an object from another object, space or substance 
(Seitavuopio, 2006). One important surface characteristic is its free energy. The origin of 
surface energy is the net inward force on the surface molecules applied by molecules in 
the bulk (Buckton, 2002). Unlike liquids, the surface free energy of solids has a non-
uniform structure. On contact, interactions between particles depend on the energy level of 
their surfaces. A change in the solid-state form or surface polarity of a substance modifies 
its surface energy. Measurement of surface free energy for solids is complicated due to 
heterogeneity of the forces acting from the bulk on each molecule. Several methods based 
on the contact angle and vapour sorption analysis have been used to assess surface energy 
of powdered substances (Table 1). Determination of the contact angle requires powders to 
be compacted before measurements to produce a flat surface. The compaction process 
may change the superficial properties of particles. Therefore, methods based on vapour 
sorption analysis are more favourable to evaluate surface energy of powders.  
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Table 1 Methods used to determine surface energy of powders. 
Method Phenomenon Measured characteristics Reference 
 
Contact angle 
 
 
Wetting  
 
The contact angle between a 
solid surface and a drop of 
liquid placed on it 
 
Nikolakakis et al., 
2002; 
Butt et al., 2006; 
Baki et al., 2010 
 
Gravimetric 
analysis  
 
Vapour sorption 
to the powder 
surface  
 
The mass change of the 
powder due to vapour 
sorption 
 
Buckton, 1997 
 
Calorimetric 
analysis 
(Isothermal 
microcalorimetry) 
 
Vapour sorption 
to the powder 
surface 
 
The heat associated with 
sorption of vapour to the 
powder 
 
Buckton, 1999 
 
Inverse gas 
chromatography 
 
Vapour sorption 
to the powder 
surface 
 
The retention volume of 
carrier gas required to elute 
the different adsorbate 
vapours from the powder 
being investigated 
 
Schiavone et al., 
2004; Steckel et al., 
2004; Kumon et al., 
2006; Steele, 2009 
 
Surfaces of particles are characterized as having a certain degree of roughness. This 
parameter depends on the material properties and processing history of the substance. 
Particle surface roughness has an influence on the bulk characteristics of powders. 
Particles with an uneven surface are generally more interactive and may have a greater 
tendency to interlock than particles with smooth surfaces. This phenomenon may have an 
influence on powder flowability (Holgado et al., 1995). In addition, surface roughness 
may change wettability of the powder particles. This fact plays a significant role during 
coating procedures and may affect the adhesion between the coating agent and the solid 
(Muster and Prestidge, 2002).  
Optical microscopy (OM), scanning electron microscopy (SEM), laser profilometry 
and atomic force microscopy (AFM) are the most widely-used analytical techniques for 
studying the nature of surfaces of pharmaceutical materials (Seitavuopio, 2006). OM is a 
simple and fast tool to visualize particle morphology. However, due to the limited 
resolution and two-dimensional view of the specimen in focus it cannot provide accurate 
data about surface heterogeneity. SEM and AFM imaging can be used to investigate 
surface morphology at a nanometre scale. There is a large number of existing 
transformation approaches that can be applied to image analysis to obtain quantitative 
information about particle surface irregularities.  
Height parameters, wavelength parameters (mean spacing, Sm), shape parameters 
(skewness, Ssk), statistical functions and fractal dimension (D) are the commonly-used 
roughness parameters to get numeric values for particle surface topography (Fini et al., 
1996; Provder and Kunz, 1996; Li and Park, 1998; Passerini et al., 2002a; Seitavuopio, 
2006). The most important roughness height descriptors are the arithmetic average 
roughness:  
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and the root mean square roughness:  
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=
−=
n
i
iq yy
n
R
1
21
       (Eq. 2) 
where n is the number of measurements, yi is the i-th measurement of surface height and 
y  is the mean value of height over all measurements (Seitavuopio, 2006). Ra and Rq are 
different representations of the same concept, and for many surfaces can even be used 
interchangeably. It is worth to mention that these parameters are differently sensible for 
different shapes of roughness. This fact, as well as historical reasons, explains their 
simultaneous usage. 
Specific surface area (SSA) is a property of powder which represents the total surface 
area of particles per unit mass, per net volume of particles or per apparent volume of 
powder (Shinohara, 1997). Gas adsorption and air permeability are the common methods 
used to measure SSA of solid particles. The first is based on the BET theory (Brunauer et 
al., 1938) and has the advantage of determining the SSA of fine particulates, taking into 
account pores smaller than 50 nm (Heng and Chan, 1997). The air permeability technique 
measures the resistance of a porous powder bed to gas flow. The method is robust and 
quick; however, it cannot accurately determine the deep surface texture of particles. 
During powder processing, a decrease in the SSA may be used as an indicator of particle 
agglomeration and/or loss of fines (Shur et al., 2008). In addition, the measured SSA 
values of powders of the same particle size allow comparison of the roughness of particle 
surfaces (Iida et al., 2004a). 
2.1.3 Interparticulate interactions and effect of relative humidity 
The attractive forces acting in bulk powder are governed by the nature of the particles, 
predominantly the properties of their surfaces and the interfaces between them, and the 
interparticulate distances between interacting units (Führer, 1996). Interparticulate 
interactions occurring between the surfaces of the same materials are called cohesion, 
whereas interactions between unlike surfaces are called adhesion. These forces are of 
molecular and electrostatic origins. The atoms of some molecules with limited charges can 
be involved in molecular interactions that act over short distances. These interactions are 
non-specific van der Waals attractions that can be divided into ion-dipole, dipole-dipole 
and van der Waals-London interactions (Führer, 1996). Van der Waals forces of attraction 
are the main forces acting between powdered particles (Visser, 1989). The magnitude of 
the forces involved depends on the morphological properties of the particles and the 
distances between them. Generally, interactions increase with decreases in particle size, 
the roughness of particle surfaces and the separation distances. However, the surface 
topography plays a critical role for interparticular interactions and can give the opposite 
effect (Figure 1). For instance, mechanical interlocking of pharmaceutical particles due to 
a rough surface structure can lead to intensification of interparticulate interactions (Figure 
Literature review 
 
 
 
 
6 
1e,f). During pharmaceutical process operations such as mixing, sieving and grinding, 
friction between the particles causes the formation of local charges, especially on the tops 
of crystal edges and where there are crystal defects. This initiates triboelectrostatic charge 
transfer that gives rise to particle attraction. The properties of the interacting materials 
determine the magnitude of charge and hence the relative position of these materials in the 
triboelectric series. 
 
 
Figure 1 Effect of surface morphology and contact geometry on interparticular interactions; 
(a) and (b): small scale surface roughness preventing particle close contact; (c) and (d): smooth 
surface structure increasing particle interactions; (e) and (f): large scale surface roughness 
promoting particle approach due to mechanical interlocking (modified from Visser, 1989). 
Relative humidity (RH) has a strong influence on the interparticulate interactions 
within a powder bed. The impact of RH on powder cohesion and adhesion strongly 
depends on the polarity of particle surfaces. In conditions of low RH, a tightly bound 
water sorption layer may be formed on the powder particle surface (Figure 2). At points of 
close contact between particles, water layers may act as a binder and merge particles 
together through hydrogen bonds. In a humid atmosphere, water may condense on the 
powder surface, forming the capillary bridges, and join particles together due to the 
surface tension force of liquid (Führer, 1996; Iida et al., 2004a; Young and Price, 2004). 
During powder handling, relative humidity has to be routinely adjusted and controlled, 
since a water layer is able to distribute the transferred charge homogeneously over the 
surface, reducing electrostatic interactions and equilibrating the powder. In addition, at 
high humidity transferred charge can leave particles due to an exchange of water 
molecules between particle surfaces and the atmosphere, stabilizing powders and making 
them easy to deal with (Führer, 1996; Kawashima et al., 1998a). 
Residual moisture has a significant effect on stability (Mahlin et al., 2006), flow 
(Führer, 1996; Faqih et al., 2007), compactibility (York, 1981) and adhesion properties 
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(Podczeck et al., 1997; Bérard et al., 2002; Price et al., 2002; Young and Price, 2004) of 
pharmaceutical materials.  
 
Figure 2 The effect of relative humidity (RH) on the bonding mechanisms of powdered 
materials: (a) tightly bond water sorption monolayer at low RH, (b) after particle contact in a dry 
atmosphere, (c) mobile water layer at high RH (Führer, 1996). 
2.1.4 Flow and aerosolization properties of powders 
Modification and control of powder flow characteristics is of extreme importance in the 
case of DPIs, where the active substance is often micronized and, therefore, very cohesive 
(Thalberg et al., 2004). Maintaining good flowability of powders is a prerequisite for the 
successful production of tablets and capsules. Insufficient flow properties of powdered 
mixes may cause variations in the weights of tablets and capsules and, as a consequence, 
fluctuation in the API dose.  
Particle characteristics such as density, size, shape, surface roughness and surface 
energy determine the interparticulate interactions and, therefore, affect the flow properties 
of powders. Spherically-shaped particles with a smooth surface and narrow particle size 
distribution flow better than particles with irregular morphology and a broad size 
distribution. However, free-flowing particles segregate easily, causing problems in dose 
uniformity of the final product. Flowability of powders depends strongly on the particle 
size (Liu et al., 2008). Powders of small particle size are generally cohesive and poorly 
flowing. An increase in the particle size brings about an improvement in the flow 
properties of powders. Therefore, granulation of powders is usually performed to increase 
the bulk density of dusty materials and decrease the segregation tendency of powder 
mixtures with different sizes, shapes and densities of particles (Alderborn, 2002). 
Triboelectrostatic charges on particle surfaces make the powder flow properties worse 
and, consequently, cause problems in the uniformity of dosage units. Storage in conditions 
of sufficient air humidity may partly discharge the material (Führer, 1996). The effect of 
humidity on the stabilization of cohesive powders is most significant in the case of polar 
particle surfaces (Kawashima et al., 1998a).  
Several approaches have been used to measure flowability of powders (Räsänen et al., 
2003; Lindberg et al., 2004; Thalberg et al., 2004; Rios, 2006; Jiang et al., 2009; Seppälä 
et al., 2010). The flow properties of powdered material may be determined directly 
(European Pharmacopoeia (Ph. Eur.), 2005) using a flow cup, which is often vibrated, or 
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indirectly by examination of the angle of repose (Geldart et al., 2006), avalanching 
behaviour (Bhattachar et al., 2004) or yield stress (Staniforth, 2002). Good-flowing 
powders give a small angle of repose and have minimal shear stress at zero normal stress. 
Determination of the compressibility index or Carr`s index (the ratio of the difference 
between the tapped and poured densities to the tapped density) has been a convenient 
method to give an estimation of rheological properties of powders: the higher the 
compressibility index, the poorer the flowability (Carr, 1965).  
2.1.5 Consolidation and compression behaviour of powders 
Compression of powders is defined as a volume reduction mechanism of powdered 
material subjected to compressive stress. Pharmaceutical powders differ from each other 
in their consolidation behaviours during tabletting. Particles can deform plastically, 
elastically or can fragment (Figure 3). The majority of pharmaceutical powders seem to be 
strain-rate sensitive and deform viscoelastically, and the degree of deformation depends on 
the applied stress and the time of loading (Müller, 1996). 
 
 
Figure 3 Powder deformation during compression (Ragnarsson,1996). 
Before compression, particle size, shape and surface properties affect the bulk density 
of a powder. In the beginning of the tabletting process, spherically-shaped particles 
rearrange easily and produce fewer defects in the compacts than irregular species. Several 
mechanisms are simultaneously involved in the formation of bonds between particles in 
the consolidated powder. The most important of these are distance attraction forces (van 
der Waals forces, hydrogen bonds, electrostatic forces), solid bridges (sintering, melting, 
crystallization), mechanical interlocking (shape- and roughness-related), non-freely 
mobile binder bridges (adsorption layers) and bonding due to mobile liquids (capillary 
forces) (Nyström and Karehill, 1996). Relative humidity (RH) has a strong impact on the 
last two bonding mechanisms (York, 1981).  
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The majority of drug powders have poor compression and consolidation properties. 
Therefore, before tabletting a careful selection of components for the formulation is very 
important. If the main ingredient deforms plastically, the minor components should be 
brittle (Wells, 2002) since lubricant sensitivity of the former leads to insufficient bonding 
(Bolhuis and Hölzer, 1996).  
2.1.6 Dissolution and solubility of powders 
Controlled dissolution of API is of great interest in the pharmaceutical sciences. 
Dissolution is defined as the transport of molecules or ions from a solid state into a 
solution, whereas solubility is the amount of a substance that can be transferred into a 
solution until equilibrium is reached between the solution and the undissolved substance at 
given conditions. Diffusion and convection are the primary processes responsible for 
producing a dissolved drug in solution during dissolution testing (Chen and Flanagan, 
2009). Diffusion predominates at short distances, where atoms, molecules and small 
particles (<0.1 µm) are transported irreversibly from a region of high concentration to 
lower concentration. Mass transfer occurs by random molecular motion and is driven by 
an increase in entropy. Over larger distances, convection (heat mixing) is an important 
transport mechanism for material transfer.  
Temperature, pressure, the nature of the solvent, crystal characteristics, pH, and the 
presence of additives are the main factors affecting the balance of intermolecular forces 
between solvent and solute and, consequently, solubility (Heng and Chan, 1996). In 
addition to the above mentioned factors, particle size, shape and surface roughness of a 
drug determine the dissolution rate of the API powder (Ashford, 2002). Improving the 
dissolution rate is extremely important in the case of poorly water-soluble drugs. 
Particle size is a critical characteristic that affects dissolution rate and, consequently, 
therapeutic effect of a poorly-soluble API (Shaw and Carless, 1974). Generally, smaller 
particles have higher intrinsic solubility than larger ones (Heng and Chan, 1997). The 
existence of a higher interfacial free energy on smaller particles is responsible for 
formation of a thermodynamically unstable system that causes greater dissolution of them. 
Particles of the same size but with different surface morphologies may exhibit different 
dissolution times as well. Particles with a rough surface have larger specific surface areas 
and, consequently, greater dissolution rates.  
Co-processing of hydrophobic API with hydrophilic carrier or wetting agent has been 
used to avoid a decrease in the effective surface area (agglomeration) during particle size 
reduction. In addition, wetting of hydrophobic surfaces enhances penetration of the 
solvent and, consequently, improves dissolution of solids (Passerini et al., 2002b; 
Rasenack and Müller, 2002; Cavallari et al., 2005a). Additive-related defects produced in 
the crystal structure during crystallization make particles thermodynamically unstable, 
leading to faster dissolution (Chiou et al., 1976). Pharmaceutical co-crystallization 
provides a new method for enhancing the dissolution rate of poorly-soluble drugs 
(Remenar et al., 2003). On the other hand, by inclusion of hydrophobic excipients in the 
formulation, it is possible to control the release of freely-water soluble API from lipid 
microparticles (Passerini et al., 2003). 
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Granulation of powdered particles causes a marked increase in the particle size of the 
mixture, which can affect the dissolution characteristics of the API. A reduction in 
available surface area can inhibit the dissolution rate and affect bioavailability of the drug. 
However, the use of hydrophilic excipients in preparation of granules can help to avoid 
this problem and even facilitate solubilization of API (Walker et al., 2007). 
2.1.7 Solid-state properties 
Solid materials may exist as crystalline or amorphous substances. The crystalline particles 
have a specific three dimensional structure, the so-called crystal lattice, in which 
molecules and atoms are arranged in a regular manner. Amorphous substances have no 
regular long-range order in their molecules and no definite structure. The majority of 
pharmaceutical materials are crystalline and exhibit polymorphism - the ability of a solid 
to exist in more than one crystalline form (Grant, 1999). Solvent molecules can be 
incorporated into the crystal lattice. These forms are called solvates or pseudopolymorphs. 
If the solvent is water, the solvate form is termed hydrate. The different polymorphs differ 
in many physical characteristics, such as packing, thermodynamic, spectroscopic, kinetic, 
surface and mechanical properties (Kahela et al., 1983; Byrn et al., 1988; Nichols and 
Frampton, 1998; Grant, 1999; Sun and Grant, 2001). The differences in solubility and 
dissolution rate between polymorphic forms of the same substance are the most important 
for pharmaceutical applications. The use of metastable polymorphs in comparison with the 
stable forms results in higher dissolution rate (Guillory, 1999). Hydrated crystals tend to 
exhibit slower dissolution rate in water than their anhydrous forms (Aaltonen et al., 2006). 
The aqueous solubility of non-aqueous solvates is often higher than that of the non-
solvated counterparts if solvates formed from water-miscible solvents (Grant and Higuchi, 
1990; Heng and Chan, 1997). Amorphous substances are more soluble than the 
corresponding crystalline solids. Any change in the crystalline form may affect the 
therapeutic efficacy of a pharmaceutical product. For that reason, process induced 
transformation (PIT) has been widely studied over recent years. It has been reported that 
polymorphic transformations take place easily during various unit operations such as 
granulation (Aaltonen et al., 2007a), drying (Römer et al., 2008) and tabletting 
(Kogermann et al., 2007), among others. In addition, surface amorphization can happen 
during milling of lactose powder for DPIs (Young and Price, 2004), whereas the stability 
of amorphous regions depends on the surrounding atmosphere (Steckel et al., 2006). 
Therefore, PIT of pharmaceutical compounds must be well controlled to exclude 
undesirable conversion during manufacturing and storage of the product.  
The appropriate tools for solid state analysis are X-ray powder diffraction (XRPD), 
spectroscopic techniques (Raman, terahertz pulsed, infrared (IR) and near-infrared 
spectroscopy), thermal analysis (differential scanning calorimetry (DSC), 
thermogravimetric analysis), microscopic methods (hot stage microscopy, OM, SEM) and 
dynamic vapour sorption (DVS). Vibrational spectroscopy techniques are fast, non-
destructive and non-invasive tools that allow real-time process monitoring, whereas 
thermal analysis, DVS and XRPD demand sample preparation. However, spectroscopic 
methods require complex data analysis in order to extract and systematically group the 
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useful information (Lakio, 2010). All these techniques provide complementary 
information about the solid-state properties of the examined material (Römer, 2008). 
Using a combination of different methods makes it possible to obtain a more complete 
picture of the molecular structure of the substance and its transformations than use of a 
single technique (Giron et al., 2002; Aaltonen et al., 2007b).  
2.2 Particle surface engineering  
2.2.1 Particle surface smoothing  
Modification of particle surfaces may be one possibility to improve powder behaviour 
during industrial processing. Preparation of particles with smooth surfaces may decrease 
the attraction forces between them, reducing the tendency to interlock. This results in 
better flow and packing properties, which is of great importance in the production of 
tablets and capsules of uniform mass and content. By modifying particle surface 
roughness, it is possible to adjust powder demixing and aerosolization properties that are 
crucial in the preparation of ordered mixture for DPIs (Kawashima et al., 1998b; 
Podczeck, 1998; Schiavone et al., 2004).  
Many approaches have been used in the field of particle surface engineering (Davies et 
al., 1998), especially in the processing of α-lactose monohydrate (LMH) carrier surfaces 
for DPIs. Controlled crystallization of lactose from different solvents has been carried out 
to produce regular crystals with smooth surfaces (Zeng et al., 2000a,b). Iida et al. used a 
number of methods for effective surface treatment of excipient such as dissolving surface 
asperities in aqueous ethanol solution (Iida et al., 2003a) and applying shear stress in a 
high-speed powder mixer (Iida et al., 2004b). A smoothing procedure, based on wetting in 
a water-ethanol mixture with or without a ternary component (magnesium stearate) and 
drying of the lactose powder in a high-shear mixer was successfully carried out (Young et 
al., 2002; Ferrari et al., 2004). In another study, decantation with absolute ethanol 
presaturated with lactose was used to remove fines from carrier lactose powder (Islam et 
al., 2004). In addition, high-temperature experiments with alcoholic solution were 
conducted to control surface dissolution of lactose particulates (El-Sabawi et al., 2006a,b). 
One of the proposed mechanisms responsible for changes in particle morphology is related 
to the ‘Ostwald ripening’ phenomenon. The process is driven by solubility differences 
between smaller and bigger particles (Ferrari et al., 2004). Fine particulates attached to the 
surfaces of bigger particles dissolve and recrystallize in the valleys of the larger ones, 
giving rise to a smooth particle surface.  
Promising attempts have been made to improve flow and/or aerosolization properties 
of API through modification of surface characteristics. A surface treatment approach, 
based on interactions at the solid-liquid interface in a drug suspension was successfully 
applied to APIs with poor flowability (Hammouda et al., 1999; Ramadan et al., 2006). 
Molecules of solvent and impurities can interact with growing faces of crystals during 
crystallization leading to a change in morphology of ripening units (Rodríguez-Hornedo et 
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al., 2007) (Figure 4). The recrystallization of sulphadiazine, methyldopa (Hammouda et 
al., 1999), ibuprofen (Rasenack and Müller, 2002), erythromycin A dihydrate (Mirza et 
al., 2008) and salbutamol sulphate (Larhrib et al., 2003) from preselected solvents in the 
absence or presence of additives has been carried out to change the habit and surface 
topography of the drug crystals.  
 
 
Figure 4 A schematic representation of changes in crystal morphology via specific interactions 
of an additive/solvent with crystal faces (modified from Rodríguez-Hornedo et al., 2007). 
In addition, several other approaches have been used to produce particles with desired 
properties, e.g. supercritical fluid technology (Schiavone et al., 2004) and the aerosol flow 
reactor method (Eerikäinen et al., 2003). The former has been used to produce API 
particles with increased surface smoothness and decreased surface energy and, as result, 
with improved drug aerosolization. The latter has been developed to yield spherical 
nanometer-sized drug particles with smooth surfaces and a unimodal size distribution. 
2.2.2 Coating of powders 
Coating of powder particles can be performed to change the nature of the powder surface 
and improve the dispersion, dissolution and flow rate of pharmaceutical bulk materials 
(Fernández-Arévalo et al., 1990; Kawashima et al., 1998a; Kawashima et al., 1998c; Chan 
and Chew, 2003). In addition, the coating of the particulate system can have a positive 
effect on taste masking, environmental protection and controlled release properties. 
However, the coating of particles is challenging due to their small size, irregular shape and 
high adhesion and cohesion, which lead to the agglomeration of individual particulates.  
Several approaches have been used for coating powder particles with liquid. Recently, 
particle thin-coating in a top-sprayed fluidized bed system has been performed to improve 
the flow properties of ibuprofen powder (Ehlers et al., 2009). A Würster fluidized bed has 
been used to cover lactose particles with a solution containing lactose and HPMC (Iida et 
al., 2005). However, both techniques are complex systems that require comprehensive 
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knowledge of the properties of materials and the influence of process variables 
(Dewettinck et al., 1999; Jono et al., 2000; Tang et al., 2008).  
Another way to coat a substance is to use a spray-drying technique. This method has 
been used to modify particle properties and enhance their manufacturing performance 
(Chan et al., 1997; Elversson and Millqvist-Fureby, 2006). The resulting spray-dried 
product is generally a free-flowing powder, but the operating equipment is very bulky and 
energy consuming. In addition, the material obtained would most likely be amorphous, 
which may lead to instability of the formulation due to recrystallization and particle fusion 
(Young and Price, 2004).  
Coating of solid particles can be performed by means of induced coacervation of the 
coating agent in a stirred suspension. The resulting microencapsulated particles can be 
separated as a powder by filtering the suspension, washing out non-encapsulated particles 
with a suitable solvent and drying the wetted material. The polymeric coating serves as a 
barrier to physicochemical degradation and can act as a release modifier for surface-
treated micro-sized drug products (Albertini et al., 2005; Sam et al., 2008). In addition, 
encapsulation of drug material is a common procedure in the preparation of nanoparticles. 
Emulsification/solvent diffusion, emulsification/solvent evaporation, nanoprecipitation 
and salting-out methods are widely-used techniques for nanoencapsulation of APIs 
(Hirsjärvi, 2008). In addition, further surface modification or functional coating of 
prepared nanoparticles can be performed to enhance stability and controlled release 
properties of APIs (Olivier et al., 1995; Nobs et al., 2003; Trimaille et al., 2003). 
Nanoparticle dispersions can be dried to a powder by means of freeze-drying and vacuum 
heating. However, the challenges in nanoencapsulation of a drug are related to low yield 
due to poor drug encapsulation efficiency, difficulties with scaling-up and removal of non-
adsorbed surface modifiers.  
The drawbacks of the above-mentioned liquid coatings, such as air pollution and long 
processing times, were overcome using an environmentally-friendly and safe dry powder 
coating technique (Pfeffer et al., 2001; Luo et al., 2008). The disadvantage of this method 
is the heat applied or generated during mechanical interactions that can cause the 
degradation of temperature-sensitive materials. 
Physical dry blending of DPI carriers with small amounts of impurities is another 
approach to improving particle surface characteristics. Covering of lactose particles with 
the antistatic compounds sucrose tristearate (J-1803F) (Iida et al., 2003b) and magnesium 
stearate (Iida et al., 2004c) has been performed to modify the superficial morphology of 
the particles. A novel mechanofusion approach in the presence of hydrophobic additives 
has been used to alter the shape and surface energy of lactose (Kumon et al., 2006). In 
addition, hydrophobic coating of polar surfaces may diminish the effect of relative 
humidity on powder stability and formulation performance (Iida et al., 2004a). Pre-
blending of lactose carriers with a fine lactose fraction can be used to enhance 
performance of DPIs (Zeng et al., 1998). Generation of fines on the surface of lactose 
excipient during milling could give the same result (Steckel et al., 2006). The effect was 
proposed to be due to occupation of the most active binding sites by fine lactose on the 
carrier surface, leaving passive sites for API adhesion. This mechanism of reduced 
adhesion between drug and carrier surface was claimed to be responsible for an increase in 
API aerosolization. In other studies, the effect of fine excipient was suggested to be related 
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to redistribution of API between the surfaces of the carrier and fine particles to form 
agglomerates consisting of fines and API particles that could improve the separation of 
API from carrier lactose (Lucas et al., 1998; Islam et al., 2004). 
2.3 Dry powder preparation of proteins 
The manufacturing of complex macromolecular compounds (e.g. proteins) presents more 
difficulties due to their labile structure. Proteins suffer from both physical and chemical 
instability and are therefore very sensitive to processing conditions (Manning et al., 1989). 
Spray-drying (Mumenthaler et al., 1994; Lucas et al., 1998; Maa et al., 1998), spray 
freeze-drying (Maa et al., 1999) and lyophilization (Carpenter et al., 1997) are the most 
common methods for the dry powder preparation of protein pharmaceuticals. However, 
these techniques have some drawbacks, such as thermal stress, shear forces, low yield and 
long processing times that can affect the stability of polypeptides (Broadhead et al., 1994; 
Ståhl et al., 2002). The spray-coating of recombinant human deoxyribonuclease onto 
microcarriers by means of top and bottom fluid bed techniques was successfully 
performed to evaluate the stability and integrity of the protein layer (Maa et al., 1996; Maa 
and Hsu, 1997). The resulting preparation was compared with the spray-dried product. 
Both techniques caused the partial loss of protein activity during the drying stage, 
although spray-drying was less damaging. However, some sources (Maa et al., 2004) 
mention that spray coating of vaccine antigens onto the carrier microparticles did not 
change the activity of the proteins. 
2.4 Ultrasound and its implementation  
2.4.1 Principles of ultrasound  
Ultrasound is a sound-like oscillation of pressure travelling through the air which is above 
the human auditory limit. More widely, it can be defined as a mechanical wave 
propagating through any form of matter (gas, liquid, solid, etc) at a frequency higher than 
20 kHz. High-power ultrasonic probes and sonotrodes consisting of electromechanical 
transducers are used in ultrasonic apparatuses for generation of energy in the form of 
sound waves (Ruecroft et al., 2005). Ultrasound can be applied at different frequencies 
and levels of intensity (Levina and Rubinstein, 2000). At low intensity, ultrasound is used 
to non-destructively study structural properties of materials. At high intensity, ultrasound 
is applied to alter physicochemical characteristics of matter irreversibly. Various effects 
derived from ultrasound-induced particle motion are responsible for changes made in the 
structural and chemical properties of materials. Most of these effects are related to heat, 
stirring, chemical activity, mechanical stress and cleansing (Levina and Rubinstein, 2000). 
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2.4.2 Implementation of ultrasound in pharmaceutical technological 
processes 
From the pharmaceutical point of view, sonochemistry and sonocrystallization are the 
most common processing applications of acoustic waves. Converted to heat, ultrasonic 
energy can accelerate or modify chemical reactions such as oxidation, polymerization, 
depolymerization and others (Ruecroft et al., 2005). In sonocrystallization, ultrasound can 
be applied to the medium to initiate primary nucleation and, consequently, to avoid 
conventional seeding. This effect is related to high energy transient cavitation and 
microstreaming (Ruecroft, 2007). Acoustic energy-based techniques have been used for 
controlled crystallization of solid materials to produce crystals with desired 
physicochemical properties using the technology designed by Prosonix (Kaerger and 
Price, 2004; Ruecroft et al., 2005; Ruecroft, 2007). Nucleation of the low-saturated 
solution, initiated by a short ultrasound pulse, gives rise to the growth of large crystals, 
whereas continuous sonication of the medium yields small crystals (Ruecroft, 2007). By 
selection and optimization of ultrasound parameters, it is also possible to achieve 
crystallization of the stable polymorphic form. In addition, combined particles consisting 
of two or more different APIs or API and excipient have been prepared by an ultrasound-
assisted technique that raises new possibilities for particle engineering (Ruecroft, 2007; 
Pitchayajittipong et al., 2009). 
Besides sonocrystallization, ultrasound has been used to improve fluidization of 
nanoparticle agglomerates (Zhu et al., 2004). Additionally, acoustic wave-based 
techniques have been used for dry granulation during compact formation (Fini et al., 2002; 
Cavallari et al., 2005b; Passerini et al., 2006), ultrasound-assisted powder compression 
(Levina and Rubinstein, 2000; Levina and Rubinstein, 2002), homogenization of 
nanoparticle preparations (Hirsjärvi, 2008), dispersion of suspended particles and 
cleaning. Spray-congealing technology using an ultrasound atomizer has been used to 
obtain surface-modified microparticles (Rodriguez et al., 1999; Albertini et al., 2005; 
Cavallari et al., 2005a). Recently, ultrasound-assisted extrusion and cutting has been 
applied to the processing of viscous amorphous materials with a low glass transition 
temperature (Hoppu et al., 2009a,b). 
Atomization of aqueous solutions by means of an ultrasonic nebulizer has been widely 
used in pulmonary drug delivery to produce a cold mist where the size of droplets is less 
than 8 µm (Omron-healthcare, 2010). The small size range is vital to guarantee the 
deposition of API into the airways. The size distribution of droplets in atomized solutions 
is also extremely important in coating operations for pharmaceutical powders. Smaller 
droplets reduce the risk of agglomerate formation and result in a powder formulation with 
better performance (Maa et al., 2004). However, the ultrasound-induced increase in the 
solution temperature may have an effect on the stability of heat-sensitive pharmaceutical 
molecules (Taylor, 2002). In the case of coating with a protein solution, foaming during 
atomization might provoke loss of the native protein structure and aggregation of the 
macromolecules, with a further loss of activity (Branchu et al., 1999). Nebulized droplets 
possess a large air-liquid interface that might also affect the stability of bioactive 
compounds (Niven et al., 1996).  
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Degradation of pharmaceutical residues by means of ultrasound waves has been 
studied to determine whether it might have a promising future in the area of wastewater 
treatment. Sonolysis of ibuprofen (Méndez-Arriaga et al., 2008), and levodopa and 
paracetamol (Quesada-Peñate et al., 2009) has been successfully performed for 
remediation of aqueous solutions.  
2.4.3 Application of ultrasound beyond the pharmaceutical field 
Beyond pharmaceuticals, ultrasound has been widely used in many different areas such as 
diagnostic sonography, cleaning, biological cell disintegration, plastic welding, foam 
extrusion and under-water ranging (Ruecroft et al., 2005). Additionally, acoustic energy 
has been applied to a variety of activities in the food processing industry. Mixing, 
homogenization, tenderization of meat and degassing are related to the mechanical effects 
of ultrasound, whereas bactericidal action, alteration of enzyme activity, sterilization of 
equipment and others are related to chemical and biological effects (Hoppu, 2008). 
2.5 Content uniformity of low-dose solid dosage forms 
The uniform distribution of highly potent API during preformulation and the preservation 
of content uniformity during further processing are essential for obtaining the correct 
effect in the final product. Poor content uniformity of the formulation can lead to a 
fluctuation in the dose. Single dose ineffectiveness can be a consequence of insufficient 
API, while an overdose can cause toxic side effects. Both situations pose health risks to 
patients.  
2.5.1 Direct compression versus granulation 
It is well known that direct compression is a cost effective method for tablet 
manufacturing because it requires fewer unit operations. In addition, it avoids stability 
problems during formulation due to the absence of moisture and heat during the process 
(Jivrai et al., 2000). However, direct compression has some disadvantages such as 
segregation of the physical mixture, as well as cohesion of drug substances during mixing 
and tabletting (Prescott and Hossfeld, 1994; Bolhuis and Chowhan, 1996). These 
limitations are of most concern if a low-dose drug with a narrow therapeutic index and 
high toxicity is in use. Because of that, an intermediate wet or dry granulation of the 
mixture is usually performed to increase the bulk density of the powder and distribute the 
API uniformly (Thiel and Nguyen, 1982; Thiel et al., 1986; Michoel et al., 1988; Wan et 
al., 1992; Greaves et al., 1995; de Haan and Thys, 1997; Parikh, 1997; am Ende et al., 
2007). In wet granulation, the drug compound can be dissolved or suspended in the 
granulation liquid, or it can be a part of the powder mixture intended for granulation. 
Nevertheless, granulation is a complicated processing stage that involves several steps and 
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adds extra costs to tablet manufacture. In addition, it causes a noticeable increase in the 
particle size of the mixture, which can affect various characteristics of the API, with the 
dissolution rate being the most important one. 
2.5.2 Improvement of content uniformity of low-dose solid dosage forms 
Besides granulation processes, several other approaches have been used to improve 
content uniformity of low-dose solid dosage forms. The sandwich method and geometric 
mixing of API and carrier lactose particles have been widely applied for preparation of 
low-dose ordered mixtures intended for lung delivery (Hersey, 1975; Wu et al., 2000; 
Schiavone et al., 2004; Steckel et al., 2006). In a United States patent (de Haan and 
Deurloo, 1995), ordered mixing of micronized steroidal compounds and excipients was 
performed to design low-dose solid dosage forms. However, in this case, only carefully 
preselected diluents with superior binding properties and very low demixing potentials 
could be successfully used to obtain a sufficiently homogeneous mixture. In another case 
(Lerner, 1971), a very potent medical compound was deposited onto the surface of the 
excipient by dissolving the drug in an organic solvent such as chloroform, mixing the 
solution obtained with carrier particles, and drying the mixture. A structured system was 
successfully obtained, but the use of unsafe volatile liquids is strongly criticized 
nowadays. Spray-drying of an alcoholic suspension containing dissolved API and 
dispersed adjuvant particles was carried out to produce a preformulation with the drug 
substance adhering to the surface of the carrier particles (Grawe et al., 2001). This 
admixture can be further dry blended with directly compressible excipients to produce 
solid dosage forms of a uniform content, avoiding demixing and sizing effects. By using a 
fluid bed technique, it was possible to coat particles of an ordered mixture with polymer 
multilayers (Thiel and Nguyen, 1984; Thiel and Sberna, 1986). This method provided a 
free-flowing product with good content uniformity and low demixing potential. In 
addition, the fluidized bed technique has been used to spray API solution onto sugar 
spheres in order to produce a homogeneous drug layer without any significant change in 
the particle size distribution of carrier particles (Martinez et al., 2001).  
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3 Aims of the study 
The primary goal of this thesis was to develop a new ultrasound-assisted technique for 
controlled thin-coating and modification of particle surfaces of pharmaceutical powders. 
 
The specific objectives of this study were: 
 
1. to minimize surface free energy and improve flowability of poorly-flowing 
powders by aqueous smoothing of particle surfaces (I) 
 
2. to optimize flowability of a cohesive API powder using polymer thin-
coating (II) 
 
3. to increase the utilization of lactose-containing pharmaceutical 
formulations for a population with adverse reactions to milk sugar by nano-
coating powdered lactose particles with the labile enzyme β-galactosidase 
(III) 
 
4. to develop a method for precise determination of coating efficiency of the 
presented technique (III, IV) 
 
5. to demonstrate the superiority of the API-coated powder approach over 
conventional physical powder blending methods in terms of content 
uniformity in low-dose tablets (IV) 
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4 Experimental 
4.1 Materials 
Thiamine hydrochloride (USP, Hawkins, Minneapolis, MN, USA) (I), β-galactosidase 
(Lactase 14-DS, Nagoya, Japan) (III) and riboflavin sodium phosphate (RSP) (Ph. Eur., 
Fluka Analytical, Sigma-Aldrich, France) (IV) were used as water-soluble model drugs. 
Ibuprofen (IBUPROFEN 50, Boots Pharmaceuticals, U.K.) (II) was used as a poorly-
flowing, practically water-insoluble model drug. Two grades of LMH (coarser grade 
Pharmatose® 80M (I, III) and finer grade Pharmatose® 200M (I), Division of Campina 
BV, the Netherlands), hydroxypropyl methylcellulose (HPMC) (Methocel E5 Premium 
LV EP, Dow Chemical Company, USA) (II) and microcrystalline cellulose (MCC) 
(Avicel® PH-200, FMC, Ireland) (IV) were utilized as model excipients. The standardized 
reagents for the ultraviolet (UV) method (R-Biopharm, Darmstadt, Germany) (III) were 
used for a quantitative determination of coating efficiency. Purified water (I-IV) was used 
as a solvent. 
4.2 Methods 
4.2.1 Particle coating and surface modification (I-IV) 
The method for particle coating (II-IV) and surface modification (I-IV) of powders has 
been developed at the Division of Pharmaceutical Technology, University of Helsinki. A 
schematic diagram of the technique is presented in Figure 5.  
 
5
1
2
 
Figure 5 Schematic diagram of the developed technique: (1) ultrasound nebulizer, (2) 
vibrating feeder, (3) solid powder, (4) stirrer (I-III) and (5) collector (the dimensions of the 
system are given in millimetres). 
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In study I, the powder particles of lactose and thiamine as solid substances were 
supplied by a vibratory feeder (Fritsch Laborette 24, Germany) and exposed to the 
instantaneous effect of a stream of pure water mist generated from an ultrasound nebulizer 
(Ultrasonic Nebuliser NE-U17, Ultra Air, Omron, the Netherlands). The droplet size of the 
water mist was approximately 1 to 8 µm (Omron-healthcare, 2010). In studies II-IV, a 
mist of coating solution was applied to the surface of carrier particles. Due to the open 
setup of the technique, some loss of coating agent occurred during the entire coating 
procedure. In studies I-III, powders were occasionally mixed by a stirrer (IKA®-WERKE, 
RW 11 basic, Staufen, Germany) to prevent the formation of liquid bridges between 
individual particles. No stirring of the surface-covered cellulose was performed in study 
IV. In total, 5 (I) and 30 (II-IV) treatment cycles were done with the same solid material. 
Representative samples of 5 g (III, IV) and 20 g (II) were withdrawn every 5th cycle. 
After the last treatment round, slightly wetted powders were left to equilibrate in ambient 
conditions. In study IV, the experimental procedures were performed in a dim room to 
minimize the destructive effect of light on the riboflavin salt. All process parameters (I-
IV) are summarized in Table 2. 
Table 2 Applied process parameters. 
 
Study I Study II Study III Study IV 
Batch size (g) 200-250 120 33 350 
Number of cycles 5 30 30 30 
Time between 
cycles (min) 
10 10 7 2 
Feeding rate of 
powder (g/min) 
7.3-42.3 2.2 2.3 9.7 
Air flow (L/min) 17 17 17 8.5 
Flow rate of mist 
(g/min) 
3.0 3.0 2.8 1.1 
Coating agent - HPMC β-galactosidase RSP 
Amount of coating 
agent in solution 
(%, m/V) 
- 0.15 1 4 
Carrier particles LMH, 
Thiamine·HCl 
Ibuprofen LMH MCC 
Rotation rate of 
stirrer (rpm) 
240 240 240 - 
Sample size (g) - 20 5 5 
Yield (%) 98.1-99.5 95.2 90.0 - 
Equilibration time 
before packing (h) 
1 1 1 24 
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4.2.2 Particle size and morphology (I-IV) 
4.2.2.1 Spatial filtering technique (SFT) (I, II) 
The measurements of particle size and size distribution were performed by the SFT 
(Petrak, 2002). The samples were fed into the SFT apparatus (Parsum® IPP 70; 
Gesellschaft für Partikel-, Strömungs und Umweltmesstechnik GmbH, Chemnitz, 
Germany) through the orifice (diameter 4 mm) using a funnel and dispersed by 
pressurized air. The chord length of each particle that passed through the laser light beam 
was transformed to particle size for subsequent data analysis (n = 3).  
4.2.2.2  Laser diffractometry (III) 
A Malvern laser diffractometer (Malvern 2600c, Malvern, England) was used to measure 
the particle size distribution of powders in an isopropyl alcohol suspension (n = 3).  
4.2.2.3 Sieve analysis (IV) 
An automatic sieve shaker (Fritsch analysette, Germany) was used to measure the particle 
size distributions of the powders using the following sieves: 45, 71, 90, 125, 180, 250, 355 
and 500 µm. The sample size was 5 g. A stacked set of the sieves was shaken for 5 min 
with an amplitude setting value of 6 (n = 3).  
4.2.2.4  Scanning electron microscopy (SEM) (I-IV) 
The morphological properties of the powders were investigated using SEM (Zeiss DSM 
962, Carl Zeiss, Oberkochen, Germany). Before scanning, the samples were coated with 
platinum using a vacuum evaporator. SEM images were acquired at an acceleration 
voltage of 10 kV. 
4.2.2.5 Atomic force microscopy (AFM) (I, II) 
The detailed surface texture of the particles was studied by AFM (Autoprobe CP, 
Thermomicroscopes, USA) over 5 µm x 5 µm (I, II) and 10 µm x 10 µm (I) areas. AFM 
mapping was performed in noncontact (I) and contact (II) modes. AFM imaging was 
carried out in ambient conditions using a large area scanner (100 µm lateral scan size). 
The average roughness parameter (Ra) (AFM User's guide, 1998) for each sample was 
calculated (n = 5-6).  
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4.2.2.6 Inverted fluorescence microscopy (IFM) (IV) 
In study IV, RSP is autofluorescent (Guo et al., 1999) and therefore, IFM (Olympus 
IX71/IX51, Olympus Optical Co., LTD, Japan) was used to determine the homogeneity of 
the API surface coating of the carrier particles and to visualize the distribution of API 
within the binary mixture.  
4.2.2.7 Stereomicroscopy (SM) and digital imaging (IV) 
SM (Leica M26, Germany) in connection with a digital camera (DC) was used to acquire 
colour images of prepared powders and tablets at a magnification of 0.63x. The powder 
samples were photographed using a separate DC (Casio EX-F1, Japan). 
4.2.3 Moisture content (I-IV) 
An IR moisture analyser (Sartorius MA 100, Sartorius AG, Germany) was used to 
determine the moisture content of the powders based on loss of weight at 105°C (I, III, 
IV) (n = 3). The measurements of the water activity of the samples (n = 3) were made 
using an AquaLab water activity meter (AquaLab 3 TE, Decagon Devices, Inc., 
Washington, DC, USA) (II-IV).  
4.2.4 Particle packing and flow properties (I, II) 
The flow characteristics of powders were measured using a new method for a direct 
determination of flow rate of very cohesive powders on a small scale (Seppälä et al., 2010) 
(I, II) (Figure 6). The system, which implements the method introduced here, induces up 
and down movements of the sample holder that are sufficient to discharge poorly flowable 
powders through the orifice onto the analytical scale. Using the data collected from the 
scale and other input parameters (e.g. dimensions of the sample holder, elapsed time), a 
computer calculates the flow rate (mg/s and µl/s) of powder particles (n = 3-5). In study 
II, the samples were equilibrated for 72 hours at different levels of controlled RH (low (26 
± 4%), intermediate (50 ± 2%) and high (70 ± 3%)) to evaluate the effect of RH on the 
rheological properties of powders.  
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Figure 6 Block diagram of the powder flow measuring arrangement (Seppälä et al., 2010). 
In study I, the angle of repose was measured according to the modified method 
presented by Zeng et al. (2000a). Powder particles were poured into a copper tube (2.8 cm 
x 3.15 cm), which had been placed vertically over a flat metal base with a diameter of 3.0 
cm. After the powder filled the tube completely, it was slowly raised vertically, leaving a 
cone of powder. The cones were photographed by a digital camera (Olympus Stylus 820 I 
µ  820, Hamburg, Germany) using super macro mode. Analysis of pictures was done by 
Matlab software (version 7). The angle of repose was calculated from the tangent (cone 
height/cone base radius) (n = 3).  
To evaluate packing properties of powders, the bulk density was determined from the 
mass of analysed material occupying 150 ml volume (I). The flow rate as a practical 
property, describing flowability, was determined as the time for a fixed amount of powder 
(50.0 g) to flow through a glass tunnel with a standard orifice diameter according to the 
method described in Ph. Eur. 5 (n = 3) (I). 
4.2.5 Solid-state properties (I-III) 
4.2.5.1 X-ray powder diffraction (XRPD) (I, II) 
Treated and untreated samples were analysed with a theta-theta X-ray diffractometer (D8 
Advance, Bruker AXS GmbH, Karlsruhe, Germany). Measurements were performed in 
symmetrical reflection mode with Cu Kα radiation (λ=1.54 Å) using a Göbel mirror.  
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4.2.5.2 Differential scanning calorimetry (DSC) (I, III) 
Calorimetric analysis was carried out in a differential scanning calorimeter (Mettler 
Toledo DSC 823e, Greifensee, Switzerland). The sample sizes were 4.5±0.5 mg (I) and 
9±1 mg (I, III) in 40-µl aluminium pans with two pinholes. The heating rate was 
10°C/min, and the cooling rate approximately 70°C/min. 
4.2.5.3 Raman spectroscopy (III) 
The Raman spectra were collected using a Raman spectrometer (PhAT SystemTM, 
RamanRXN1TM, Kaiser Optical System Inc., Ann Arbor, MI, USA) equipped with a fibre-
optically coupled PhAT probe head. All Raman spectra were acquired using HoloGram 
software (HoloProTM, Kaiser Optical System Inc., Ann Arbor, MI, USA). 
4.2.6 Determination of enzyme activity, coating efficiency and stability of 
enzyme preparations (III) 
To measure the enzyme activity in solution, a standardized spectrophotometry method (R-
Biopharm, 2010) was used. The standard curve was obtained after incubation of 200 mg of 
LMH and 200 mg of lactase powder in 100 mL of purified water. To determine the effect 
of ultrasound-assisted nebulization on β-galactosidase activity, a 1% (m/V) protein 
solution was prepared, part of the enzyme solution was used as prepared, and another part 
was atomized and the mist containing β-galactosidase was collected as a fluid. Both 
solutions were used to prepare intermediate solutions containing 0.005-0.2 g/L of enzyme 
and 1.9 g/L of lactose. These solutions were incubated for precisely 24 h at 22±1°C and 
assayed.  
To measure the change in the amount of surface-attached β-galactosidase during the 
coating procedure, 200 mg of coated powder from each sample was dissolved in 100 mL 
of purified water. The solutions were incubated and analysed. The stability of the β-
galactosidase preparation was tested after two weeks and after one month of storage. 
To evaluate the potential enzymatic degradation of lactose during the treatment 
procedure, 200 mg of the final freshly-coated powder was dissolved in 100 mL of purified 
water and assayed immediately for D-galactose without incubation. The same procedure 
was conducted with raw LMH, and the results were compared.  
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4.2.7 Properties of API-coated MCC powder in comparison with physical 
mixtures of MCC and API (IV) 
4.2.7.1 Riboflavin content of the coated powder and physical mixture 
In order to determine the coating efficiency of the described procedure, the withdrawn 
representative samples were analysed for RSP content. Two hundred fifty milligrams of 
the treated powder from each sample (n = 3) was suspended in 100 mL of water. The 
absorbance of the filtered solution was measured at 444 nm using a UV-Vis 
spectrophotometer (Pharmacia Ultrospec III, Pegasus Scientific Inc., Rockville, MD, 
USA). To generate the standard curve, 200 mg of RSP and 2300 mg of MCC were used to 
prepare 0.2 mg/mL stock solution of RSP in water. 
A physical mixture of RSP and MCC was prepared to compare formulations. To 
calculate the exact amount of API required for getting a binary mix with the same RSP 
content as in the coated powder, the latter (250 mg of powder in 100 mL of water, n = 11) 
was assayed at 444 nm. The total mass of the physical mixture was 310 g. The powder 
components were placed in the glass jar and the RSP placed in the middle of the MCC 
powder. The powders were mixed for 30 min with a rotation speed of 46 rpm in a Turbula 
blender (Willy A. Bachofen AG Maschinenfabrik, Basel, Switzerland). The physical 
mixture was assessed for content uniformity of RSP (250 mg of powder in 100 mL of 
water, n = 11) by taking samples from different locations in the blender. The standard 
deviation (SD) and the relative standard deviation (Srel) were calculated. 
4.2.7.2 Tabletting and tablet properties 
Lubricant-free tablets were compressed from both the coated powder and the physical 
mixture by using an instrumented single punch tabletting machine (Korsch EK-0, Erweka 
Apparatebau, Berlin, Germany) equipped with flat-faced 9-mm punches. The compression 
force used was 2.3 kN for both formulations. The batch size was 950 tablets with a speed 
of 37 tablets per minute. The device was set up to produce tablets with a target weight of 
250 mg and a target crushing strength of 90 N. The same settings were used for the coated 
powder as for the physically mixed reference powder. The tablets were collected 
sequentially one by one into the plastic tubes: 100 tablets per tube.  
To analyse the homogeneity of mass and content of low-dose forms and observe the 
differences in these parameters with tabletting time, the first 10 tablets in the series from 
each sequential tube were weighed individually and assayed at 444 nm using a UV-Vis 
spectrophotometer (Pharmacia Ultrospec III, Pegasus Scientific Inc., Rockville, MD, 
USA).  
Surface coating of the MCC particles with the API could have an impact on the 
mechanical properties of tablets prepared from this powder. Therefore, the crushing 
strength of tablets was measured by using a crushing strength device (Schleuniger-2E, Dr. 
K. Schleuniger & Co, Germany) (n = 100). 
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5 Results and discussion 
5.1 Moisture content (I-IV) 
In studies I-III, the treatment by successive steps of ultrasound-assisted spraying of water 
(I), polymer (II) or protein (III) mist and a brief equilibration of the powder bed did not 
give any increase in the water content of modified samples. The values for water activity 
were in good agreement with those for the processing environment. Obviously, the open 
setup of the ultrasound technique facilitates the evaporation of excessive liquid during 
processing and, hence, makes an additional drying step unnecessary. It in turn prevents the 
attrition and breakage of the treated powder, minimizing coating defects (II, III). In study 
IV, the water content of the processed powders increased slightly during the coating 
procedure. However, keeping the treated and untreated materials in ambient conditions for 
one day equilibrated the moisture content of the powders.  
5.2 Morphological properties (I-IV) 
5.2.1 Particle size distribution (I-IV) 
Permanent binding of particles to each other (as a result of cohesion and adhesion forces, 
capillary pressure, solid bridges, etc) can take place during the water mist treatment and 
coating procedure (Maa and Hsu, 1997). This leads to a broader particle size distribution. 
Agglomerated particles behave as granules and lose their native powder characteristics. 
Therefore, prevention of particle agglomeration was highly desirable. In all studies (I-IV), 
particle surfaces of powders were modified successfully without granule formation, 
whereas particle size characteristics remained practically unchanged. A slight increase in 
the particle size of the processed powders was sometimes observed. This was most likely 
due to dissolution of fines and their subsequent recrystallization on the surface of the 
larger species (I, III) as well as due to a thin API layer on the surface of the carrier 
particles (III, IV). Besides, loss of dust could take place as a result of the open setup of 
the technique. However, in study II, the values of size descriptors of the surface-treated 
powders slightly decreased in comparison with the raw material. Obviously, a thin HPMC 
coat on the surface of individual particles provided a barrier that reduced the cohesiveness 
of the ibuprofen powder. 
5.2.2 Particle surface properties (I-IV) 
In study I, the surface of treated lactose particles became smoother, whereas the shape of 
the particles remained almost unchanged (Figure 7). The aqueous mist, applied directly to 
the powder brought about dissolution of superficial prominences and fine particulates. 
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Dissolved material was most probably deposited in the pits of bigger particles due to the 
‘Ostwald ripening’ phenomenon (Ferrari et al., 2004), making particle surfaces smoother. 
For flake-like particles of thiamine, it was difficult to draw clear conclusions based on 
visual observations of the changes in the surface topography (Figure 7).  
 
 
Figure 7 Scanning electron micrographs of untreated (a) and treated (b) coarser grade lactose 
monohydrate (LMH); untreated (c) and treated (d) finer grade LMH; untreated (e) and treated (f) 
thiamine hydrochloride powders. 
Representative AFM images obtained over 5 µm x 5 µm areas (Figure 8) showed a 
decrease in surface roughness of powder particles after water mist processing. The directly 
measured Ra parameter confirmed this observation: the decreased values of Ra over 5 µm 
x 5 µm areas were obtained for all aqueous-mist treated samples. 
 
Figure 8 Representative AFM height images showing particle surface roughness of untreated 
(a) and treated (b) coarser grade lactose monohydrate (LMH); untreated (c) and treated (d) finer 
grade LMH; untreated (e) and treated (f) thiamine hydrochloride powders. 
Particle thin-coating gave rise to a relatively smooth polymer layer on the surface of 
rough ibuprofen species (II). During progressive enzyme coating of LMH, the surface of 
modified lactose particles became smoother as well (III). After the last coating cycles, the 
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surfaces of the carrier particles appeared to be visually smooth (Figure 9). However, using 
straight visual examinations, it was not possible to identify individual coating layers. 
Therefore, in study IV, the carrier particles were coated with autofluorescent API to 
observe the coating film on the particle surfaces (Figure 10). In addition, it made it 
possible to compare distribution of the active substance within the RSP-coated powder 
with the homogeneity of the reference physical mixture. API coating produced a uniform 
drug layer on the surface of the carrier particles. The formulation used for direct 
compression appeared to be a random mixture, where API agglomerates of spherical 
particles were still observable. The cohesive nature of RSP, which is related to its small 
particle size, prevented the homogeneous dispersion of API particles within the physical 
system. 
 
Figure 9 Scanning electron micrographs of untreated and β-galactosidase-coated lactose 
monohydrate (LMH) powder after 15 and 30 cycles of treatment. 
   
Figure 10 The inverted fluorescence microscope images of raw riboflavin sodium phosphate 
(A), microcrystalline cellulose (B), the physical mixture of powders (C) and the surface-coated 
powder (D). 
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5.3 Powder rheological properties (I, II) 
5.3.1 Flow and packing properties (I, II) 
An aqueous mist treatment at the solid-liquid-air interface was expected to decrease 
particle surface roughness and cause changes in the particle size range. The smoothing 
procedure was supposed to reduce the internal friction between particles and improve the 
flow rate of the powder. Results from the new flowability measurement tool (cf. 4.2.4) 
revealed that flow rates of surface-treated coarser LMH and thiamine powders increased 
approximately two fold, whereas the flowability of finer lactose tended to improve slightly 
less (Table 3). A similar increase in the flow rate of coarser LMH was obtained from the 
flowability test done according to Ph. Eur. (18.0 ± 1.7 g/s for raw material and 28.3 ± 0.32 
g/s for surface-modified substance). The impossibility of applying the last method for 
poorly-flowing powders highlights the usefulness of the new flowability measurement 
tool.  
Table 3 Flowability, angle of repose and bulk density values for water mist treated and 
untreated materials (data are presented as mean ± SD, n = 3). 
* p<0.01, significant difference compared to untreated substance by Student's unpaired t-test 
 
The smaller values of angle of repose for processed powders underlined the fact that 
treated substances exhibited superior flowability in comparison with the original materials. 
But the angle of repose was less sensitive to the changes in flow properties of modified 
powders than the values obtained using the new flowability measurement technique. Only 
coarser lactose showed statistically significant reductions in the angle values. This could 
be due to the fact that the angle of repose is determined by the least stable particles (Zeng 
et al., 2000a), whereas the results from the new tool depend primarily on the bulk 
properties of the powder bed. Also, more dense packing was observed for processed 
coarser LMH and thiamine samples. Their poured densities increased significantly.  
Improvement in the flow properties of the coarser lactose was probably due to 
smoothing of surfaces and a decrease in the level of fines with a very slight increment in 
particle size. The changes in mechanical characteristics of thiamine powder were assumed 
Sample Flowability 
  
mg/s 
 
µl/s 
Angle of 
repose 
(Degrees) 
Bulk density 
 
g/cm3 
 
LMH coarser grade, untreated 
 
86.5±7.6 
 
146±11 
 
49.6±0.66 
 
0.766±0.009 
LMH coarser grade, treated 
 
174±10* 278±21* 46.5±0.79* 0.787±0.005* 
LMH finer grade, untreated 9.30±1.7 23.8±3.7 56.5±2.1 0.505±0.007 
LMH finer grade, treated 
 
11.4±1.7 29.3±5.5 54.8±1.9 0.501±0.008 
Thiamine·HCl, untreated 6.39±0.61 24.1±2.1 64.9±0.11 0.326±0.004 
Thiamine·HCl, treated 12.1±0.66* 41.5±2.3* 62.6±1.8 0.361±0.004* 
Results and discussion 
 
 
 
 
30 
to be mainly due to a narrowing of the particle size distribution, whereas the tendency for 
better flow properties of finer lactose was related to surface and size modifications.  
In study II, HPMC thin-coating improved the flow characteristics of ibuprofen powder 
(Figure 11). The higher number of cycles gave a more uniform coating of particle 
surfaces, as can be seen from the gradual growth in the flow rate. It increased greatly after 
twenty-five cycles of treatment, whereas further processing did not give any significant 
improvement. Obviously, the raw surface of ibuprofen particles has already been 
completely hidden by polymer thin-coat after twenty-five cycles of treatment. The effect 
of the coating layer on the flow properties of the powder could be explained by the 
increase in the hydrophilicity of particle surfaces, which reduced electrostatic interactions 
and thus decreased the cohesive forces between hydrophobic ibuprofen particles. The 
influence of hydrophilic species on the flow properties of hydrophobic substances was 
previously reported by other authors (Kawashima et al., 1998a).  
5.3.2 The effect of relative humidity on flow properties (II) 
It is a well-known fact that moisture has a significant influence on the flow properties of 
cohesive powders (Forsyth et al., 2002; Faqih et al., 2007). In study II, it was found that 
the flow rate decreased as the water content of the surface-treated powders increased 
(Figure 11). It is obvious that at high relative humidity the water vapour condensed onto 
particle surfaces, creating a water sorption layer (Führer, 1996; Nyström and Karehill, 
1996). A further increase in relative humidity caused separation of the water phase, which 
gave rise to capillary forces (Iida et al., 2004a). These liquid interactions held particles 
together, preventing their flow. The effect of humidity on the flow properties of the 
modified powder became more noticeable when the uniformity of the HPMC layer 
increased. The thin-polymer coating made the surface of the ibuprofen particles more 
hydrophilic, as mentioned above. The hydrophilic surface had more affinity for water 
molecules and as a consequence became more subject to pronounced capillary effects. As 
well, the smoother surfaces of HPMC-coated particles could have enhanced hydrostatic 
forces (Podczeck et al., 1997). At low water activity levels, having less adsorbed water 
probably acted as a lubricant, facilitating powder flow (Kaerger et al., 2004). Changes in 
water activity did not have a significant effect on the flowing characteristics of the raw 
material.  
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Figure 11 The influences of the uniformity of the HPMC coating layer and relative humidity on 
the flow properties of ibuprofen powders (n = 5). 
5.4 API-coating of carrier powder (III, IV) 
5.4.1 Protein mist coating (III) 
In study II, thin-coating of ibuprofen particles with HPMC was performed to reduce the 
cohesiveness of the highly charged material and improve the flow properties of the 
powder. However, the increase in the thickness of the coating layer was measured with an 
indirect method, and quantitative analysis of the particle coat was not performed. Thus, the 
coating efficiency of our technique needed to be determined. There were several reasons 
for selecting β-galactosidase as a model substance. Firstly, the stability of the nebulized 
product needed to be checked, and β-galactosidase is a fragile molecule that can lose its 
activity very easily. Secondly, a precise method exists for the determination of the 
substrate/product concentration for the β-galactosidase reaction, and consequently, the 
amount of enzyme. The method is well standardized since the quantitative estimation of 
lactose in diary products is a common procedure due to the large number of people with 
lactose intolerance (Onwulata et al., 1989; Montalto et al., 2005; O’Connell and Walsh, 
2006). Thirdly, it can provide proof that the surface-modified powder remained dry if no 
reaction product appeared, as an enzymatic reaction requires water. The amount of D-
Results and discussion 
 
 
 
 
32 
galactose produced in the maximally treated powder in the freshly prepared solution was 
below the detection limit of the UV-Vis spectrophotometer .  
5.4.2 Effect of nebulization on β-galactosidase activity (III) 
It is well known that proteins are stress-sensitive bioactive molecules that can undergo 
irreversible conformational changes with subsequent activity loss (Yoshioka et al., 1993; 
Alavi et al., 2002; Kuny and Leuenberger, 2003). In our study the ultrasound nebulization 
did not affect the catalytic activity of lactase (Figure 12). The amount of enzyme needed to 
cleave a predetermined amount of lactose sugar was the same for the atomized protein as 
for the commercial protein.  
 
Figure 12 Retention of β-galactosidase activity before and after nebulization of the enzyme 
solution. The incubation time of substrate/enzyme solutions is 24 h. 
5.4.3 Determination of API loading (III, IV) 
In study III, the quantity of β-galactosidase on the lactose particle surface was determined 
via its reaction product, D-galactose, by UV-Vis spectrophotometry. The enzyme loading 
increased gradually with the treatment cycles, suggesting a constant increase in the 
thickness of the coating layer (1st run) (Figure 13). The stability of the enzyme preparation 
was examined after two weeks and after one month of storage. β-galactosidase tended to 
remain unchanged in its ability to cleave disaccharide bonds. Furthermore, the 
repeatability of our technique was tested by conducting an analogous coating experiment 
(2nd run). The results from the second run did not differ from those of the first. The 
technique therefore appears to give rise to an enzyme coat in a reproducible way.  
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Figure 13 Coating efficiency, expressed as amount of D-galactose (g/L) produced by a 
progressively increasing enzyme coat as the number of coating cycles increased (1st run). Stability 
of the β-galactosidase formulation prepared in the first coating experiment after 2 weeks and after 
1 month of storage (1st run) and repeatability of the technique by conducting an analogous coating 
experiment (2nd run). Error bars: mean ± standard deviation (n = 4). 
The results shown in Figure 12 and Figure 13 allow us to calculate the precise amount 
of surface-deposited enzyme material using a fitted exponential function. There were on 
average 0.5 and 5.7 mg of β-galactosidase coat per 1 g of lactose powder after 5 and 30 
cycles, respectively. This means that every coating cycle increased the amount of surface-
attached enzyme by 0.16±0.03 mg/g of treated LMH.  
From the ratio (α) between the weight of the enzyme coat and the weight of lactose 
powder, assuming that lactose particles were spheres, the thickness of the coating layer 
can be calculated according to Eq. 3:  
 
3
2
21
12
ρ
ρρα +×
×= rr                   (Eq. 3) 
where r1 and r2 are the radii of uncoated and coated lactose particles, and ρ1 and ρ2 are the 
true densities of pure lactose and enzyme powder, respectively. From the literature, ρ1 is 
1.545 g/cm3 (Rowe et al., 2009), and ρ2 is 1.42 g/cm3 (Kuny and Leuenberger, 2003). The 
volume median diameter of raw lactose particles was measured to be 226 µm.  
The calculated thickness of the β-galactosidase layer was up to 234 nm, increasing 
nearly linearly with every treatment cycle (Figure 14). The uniform increase in the 
quantity of the surface-attached protein is important for the homogeneous distribution of 
the API in the powder.  
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Figure 14 Calculated thickness of the coating layer. Error bars: mean ± standard deviation, n = 
4. The results were fitted within the approximation of error (broken line). 
In study IV, RSP coating produced an ultra-thin yellow layer on the surface of the 
polymer carriers. The colour’s intensity increased as the coating proceeded (Figure 15). A 
quantitative analysis of the surface-treated powders, taken at predetermined intervals 
during the coating procedure, also revealed a near linear increase in the thickness of the 
drug layer. This means that the amount of the surface-attached active substance can be 
controlled easily during the coating process. The results revealed that the coating was 
homogeneous, as nearly every single particle was treated with a mist of RSP solution, 
preventing the formation of ‘dead zones’ in the processed powder.  
 
    
Figure 15 The increase in the colour intensity of riboflavin sodium phosphate-treated powders 
as the number of coating cycles increased. 
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5.4.4 Content variation of API-coated and physically mixed powders (IV) 
API-coating of powdered particles offers some advantages relative to the widely applied 
mechanical mixing; with the latter method, problems are experienced with demixing due 
to cohesion of particular components, segregation of powder and formation of “dead 
spots” inside the blender.  
In study IV, the average amount of riboflavin was 1.48±0.04 mg per 250 mg of coated 
powder (Srel = 2.8%). This value was used to calculate the amount of riboflavin salt that 
needed to be added to MCC to get a physical mixture with the same quantity of the API 
for both formulations. However, we obtained a physical mixture with a lower amount of 
riboflavin: 1.31±0.08 mg per 250 mg of powder (Srel = 5.7%). It appeared that some API 
stuck to the walls and to the cork of the bottle. This observation, and a higher SD in 
riboflavin content within the physical mixture in comparison with the coated powder, 
could indicate that the physical mixture was not completely homogeneous and that areas 
of high and low drug content were formed.  
5.4.5 Weight and content variation of tablets (IV) 
Since tablets are the final product and the most convenient solid dosage forms, compacts 
from API-coated powder and the physical mixture of both components were prepared to 
evaluate the weight and content uniformity. Tablets from both formulations were 
successfully compressed without addition of lubricant. API coating of MCC powder did 
not change the mechanical properties of tablets significantly in comparison with tablets 
prepared from the physical mixture.  
The average mass of the tablets made from the coated powder was slightly higher, 
indicating denser packing of the powder during tablet compression: 252.4±0.9 mg (Srel = 
0.4%) for the coated powder and 247.0±1.3 mg (Srel = 0.5%) for the physical mixture. 
The denser arrangement of the solid material could be related to the changes in the surface 
properties and, consequently, in the bulk density of API-coated MCC particles. The SD 
and Srel in weight variation of compacts from the coated powder were smaller and 
consequently, the uniformity of weight was higher.  
The content variation was clearly less for the surface-treated material, where the drug 
coating gave rise to a uniform distribution of API within the powder (Figure 16). Srel (n = 
100) was almost 4 times higher for the directly compressed compacts of the physical 
mixture (6.5%) than for the tablets prepared from the RSP-coated formulation (1.8%), 
indicating a smaller long-time scale variation in the latter preparation. Additionally, the 
short-time scale variation within the first 10 compacts from each subsequent series was 
better for tablets prepared from the surface-coated powder than for tablets prepared from 
the physical mix. Obviously, segregation of the physical mixture occurred during 
tabletting, since a strong vibration of the hopper can provoke separation of the binary 
formulation. This caused an increase in the content variation of the reference tablets. 
Visual observation of the tablet surfaces confirmed the above finding (Figure 17).  
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Figure 16 The content variation of tablets prepared from the coated powder and the physical 
mixture of powders as a function of the number of tablets compressed (n = 100). 
    
Figure 17 Stereomicrographs of tablets prepared from the surface-coated powder (yellow 
tablets) and physical mixture of powders (white tablets with yellow-orange spots). Arrows point to 
poorly mixed riboflavin sodium phosphate particles (small yellow-orange spots). 
5.5 Solid-state properties (I-III) 
XRPD, DSC and Raman spectra analyses were performed in order to determine whether 
any solid state modifications had occurred on the particle surface of powders. No crystal 
lattice changes nor the halo patterns were observed after water mist treatment and thin-
coating of powder particles.  
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6 Summary and conclusions 
A new ultrasound-assisted technique for modification of particle surfaces of 
pharmaceutical powders was developed. The proposed method is promising as an effective 
and repeatable tool for improvement of the physico-technical properties of powders. This 
technique can be used to dissolve and smooth particle surfaces of water-soluble excipients 
and drug substances as well as to thin-coat cohesive APIs, giving rise to powders with 
desired characteristics. Improvement of rheological properties, measured by the novel 
flowability equipment, may have practical application for the effective processing of 
powders for DPIs as well as for direct compression of tablets. Furthermore, the introduced 
method is insensitive to batch size and environmental conditions. This technique can be 
used in an uninterrupted manner to improve the flow properties of heat, moisture and 
shear/stress sensitive powders. In addition, it can be applied to freshly milled, highly 
charged materials to make further unit operations such as granulation, weighing and 
packing easier and more cost effective.  
Uniform deposition of the enzyme β-galactosidase onto lactose particles was carried 
out by the technique presented in this thesis. During coating, overwetting of the powder 
mass and activation of the enzyme were avoided, both of which are difficult to achieve 
using more complex methods such as the fluid bed technique. Determination of the 
coating efficiency of the surface-treated powder was precisely done using a simple 
approach. The thickness of the protein layer increased progressively. Such pre-treatment 
of lactose may be useful for formulating pharmaceutical dosages for patients with lactose 
intolerance. However, further studies are required to demonstrate the pharmaceutical 
processability of the functionally coated lactose.  
By using the ultrasound-assisted technique, it was possible to make a homogeneous 
powder formulation of a low-dose API that remained uniform during the entire tabletting 
process. The API coating produced an even drug layer on the surface of the carrier 
particles. Tablets prepared from the coated powder showed significantly improved content 
uniformity in comparison with the tablets compressed from the physical mixture of the 
powders. The increase in content uniformity of low-dose tablets improves quality of the 
final dosage forms and consequently, ensures the safe delivery of a potent active substance 
to patients. However, the duration of treatment by the ultrasound-assisted technique has to 
be considered when the modification/coating procedure is done several tens of times. 
Furthermore, the method is not fully optimized to date, and the loss of mist to the 
environment has to be taken into account. 
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